Back | Next |
home / stock / kalv / kalv message board
Subject | By | Source | When |
---|---|---|---|
http://m.nasdaq.com/article/sv-life-sciences-advisers-llc-buys-kalvista-pharmace | kondziu | investorshub | 02/10/2017 10:38:41 AM |
$8.25 now ~ keep rollin | Warchest | investorshub | 01/09/2017 8:20:18 PM |
any positive news and volume will move this north | ming1234 | investorshub | 01/09/2017 8:10:52 PM |
$LIVE action starting !!! | Warchest | investorshub | 01/09/2017 6:35:11 PM |
watching close ~ | Warchest | investorshub | 01/09/2017 6:30:21 PM |
The way this is dropping, there has to | Toxic Avenger | investorshub | 12/12/2016 4:01:25 PM |
So when will CBYL holders be issued $KALV | MSparks6 | investorshub | 11/22/2016 3:06:28 PM |
$CBYL is now KALV with a 1:14 reverse | Toxic Avenger | investorshub | 11/22/2016 1:12:17 PM |
$6.00 | Iam_in | investorshub | 11/22/2016 1:08:15 PM |
New Ticker symbol now: KALV | Iam_in | investorshub | 11/22/2016 1:06:35 PM |
Correction : $5.49 PM | Iam_in | investorshub | 11/22/2016 1:03:46 PM |
WOW - look at this $0,89---> $4,60 | Iam_in | investorshub | 11/22/2016 1:01:49 PM |
Apparently the merger deal was approved by a | Toxic Avenger | investorshub | 11/22/2016 12:11:24 AM |
* * $CBYL Video Chart 11-21-16 * * | ClayTrader | investorshub | 11/21/2016 9:26:25 PM |
Attempting to break 0.72. GL to holders | beginneer | investorshub | 11/21/2016 2:49:42 PM |
We'll see how this goes. Hopefully back to | beginneer | investorshub | 11/21/2016 2:45:58 PM |
$CBYL continuing its upward momentum pre-market. | Toxic Avenger | investorshub | 11/21/2016 2:24:32 PM |
* * $CBYL Video Chart 11-18-16 * * | ClayTrader | investorshub | 11/18/2016 9:46:54 PM |
Oh okay. Im still up for it even | beginneer | investorshub | 11/18/2016 8:43:29 PM |
New buyer? They're not being bought, they're merging | Toxic Avenger | investorshub | 11/18/2016 7:59:44 PM |
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...
– US subgroup in the phase 3 KONFIDENT trial demonstrates median time to treatment of 38 minutes and time to beginning of symptom relief 1.3 hours – – Despite growing use of long-term prophylaxis therapies in the US on-demand treatment prescription volumes stay stable...